Cargando…

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease

Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vakrakou, Aigli G., Karachaliou, Eleni, Chroni, Elisabeth, Zouvelou, Vasiliki, Tzanetakos, Dimitrios, Salakou, Stavroula, Papadopoulou, Marianna, Tzartos, Socrates, Voumvourakis, Konstantinos, Kilidireas, Constantinos, Giannopoulos, Sotirios, Tsivgoulis, Georgios, Tzartos, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410455/ https://www.ncbi.nlm.nih.gov/pubmed/37564637 http://dx.doi.org/10.3389/fimmu.2023.1212757

Ejemplares similares

Potential Role of Antibodies against Aquaporin-1 in Patients with Central Nervous System Demyelination
por: Pechlivanidou, Maria, et al.
Publicado: (2023)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015)

MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine
por: Bhaskar, Shalini, et al.
Publicado: (2022)

Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)

Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)

MuSK-Associated Myasthenia Gravis: Clinical Features and Management
por: Rodolico, Carmelo, et al.
Publicado: (2020)

Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis
por: Kwon, Young Nam, et al.
Publicado: (2022)

Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity
por: Huijbers, Maartje G., et al.
Publicado: (2019)

Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis
por: Kim, Seung Woo, et al.
Publicado: (2017)

Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
por: Kordas, Gregory, et al.
Publicado: (2014)

Recent Advances in Genetic Predisposition of Myasthenia Gravis
por: Zagoriti, Zoi, et al.
Publicado: (2013)

Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
por: Zhang, Zunwei, et al.
Publicado: (2020)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes
por: Huang, Qi, et al.
Publicado: (2022)

Immunological and Structural Characterization of Titin Main Immunogenic Region; I110 Domain Is the Target of Titin Antibodies in Myasthenia Gravis
por: Stergiou, Christos, et al.
Publicado: (2023)

Cerebrospinal Fluid Anti-Neuronal Autoantibodies in COVID-19-Associated Limbic Encephalitis with Acute Cerebellar Ataxia and Myoclonus Syndrome: Case Report and Literature Review
por: Yiannopoulou, Konstantina, et al.
Publicado: (2023)

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment
por: Lanfranconi, S., et al.
Publicado: (2011)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
por: Schneider-Gold, Christiane, et al.
Publicado: (2017)

Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study
por: Kazakou, Paraskevi, et al.
Publicado: (2023)

Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis
por: Tzanetakos, Dimitrios, et al.
Publicado: (2022)

Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, Jae‐Yun, et al.
Publicado: (2016)

The impact of rituximab infusion protocol on the long‐term outcome in anti‐MuSK myasthenia gravis
por: Cortés‐Vicente, Elena, et al.
Publicado: (2018)

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis
por: Vergoossen, Dana L. E., et al.
Publicado: (2021)

Anti-MuSK Positive Myasthenia Gravis with Anti-Lrp4 and Anti-titin Antibodies
por: Yamashita, Rika, et al.
Publicado: (2020)

Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?
por: Bardakov, Sergey N., et al.
Publicado: (2022)

Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis
por: Seok, Jo Woon, et al.
Publicado: (2023)

Dental follicle mesenchymal stem cell administration ameliorates muscle weakness in MuSK-immunized mice
por: Ulusoy, Canan, et al.
Publicado: (2015)

Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)

SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
por: Huda, Saif, et al.
Publicado: (2019)

Laboratory Investigation of Hybrid IgG4 k/λ in MuSK Positive Myasthenia Gravis
por: Basile, Umberto, et al.
Publicado: (2021)

Genetics of Myasthenia Gravis: A Case-Control Association Study in the Hellenic Population
por: Zagoriti, Zoi, et al.
Publicado: (2012)

Common Denominators in the Immunobiology of IgG4 Autoimmune Diseases: What Do Glomerulonephritis, Pemphigus Vulgaris, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura and Autoimmune Encephalitis Have in Common?
por: Koneczny, Inga, et al.
Publicado: (2021)

Effects of the ß2-Adrenoceptor Agonist, Albuterol, in a Mouse Model of Anti-MuSK Myasthenia Gravis
por: Ghazanfari, Nazanin, et al.
Publicado: (2014)

Grave Prognosis of the MuscleSpecific Kinase (MuSK)-positive Myasthenia Gravis (MG): A False Prejudice
por: Hiew, Fu Liong
Publicado: (2020)

Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study
por: Meng, Xin, et al.
Publicado: (2022)

Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
por: Spagni, Gregorio, et al.
Publicado: (2022)

Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases
por: Vakrakou, Aigli G., et al.
Publicado: (2021)

Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature
por: Vakrakou, Aigli G., et al.
Publicado: (2020)

Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity
por: Shin, Ha Young, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_km8gnb1urel6ltpbl19v9ht89t